For the retreatment of sofosbuvir-containing regimen-experienced, GT1b patients with or without compensated cirrhosis, a 12-week regimen of a daily fixed-dose combination of NS3 inhibitor glecaprevir (300 mg)/NS5A inhibitor pibrentasvir (120 mg) or a 12-week regimen of a daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) is recommended [22]. The gene discussed is KRAS; the disease is Cirrhosis.